Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Dr Steven Yeh on Patients Treated With Xipere and Its Use Over the Long Term
July 14th 2022Triamcinolone acetonide injectable suspension (Xipere) uses a novel delivery mechanism that seems to benefit all patients with macular edema due to noninfectious uveitis, regardless of where the inflammation occurs, said Steven Yeh, MD, professor and the Stanley Truhlsen Jr. Chair in Ophthalmology at the Truhlsen Eye Institute, University of Nebraska Medical Center.
Read More
Dr Steven Yeh Discusses the Importance of Meeting in Person at Conferences Like ASRS
July 12th 2022Connecting with colleagues in person allows for meaningful conversations about the future of the retina care field and patients, said Steven Yeh, MD, professor and the Stanley Truhlsen Jr. Chair in Ophthalmology at the Truhlsen Eye Institute, University of Nebraska Medical Center.
Read More
Dr Debra Patt Highlights the High Usage of Digital Health Solutions at Texas Oncology
July 3rd 2022Digital health care has been a key initiative at Texas Oncology, because it ensure patients can receive better care at their home, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
Read More
Dr Debra Patt Underscores Permanent Changes Even as the OCM Ends
June 27th 2022Although the Oncology Care Model (OCM) is ending June 30, 2022, it does not mean practices can turn back the clock and revert to how they provided care prior to the OCM, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
Read More
Switching Among Infliximab Biosimilars Effective and Well Tolerated, Research Finds
June 24th 2022Among a real-world cohort of patients, switching between infliximab biosimilars was effective and well tolerated, although retention was higher among those who had initially started on the originator product.
Read More
Biosimilar Utilization Increased During the OCM and Generated Savings
June 23rd 2022Abstracts presented at the American Society of Clinical Oncology Annual Meeting evaluated biosimilar use in practices participating in the Oncology Care Model (OCM) and estimated the savings as a result of substituting these agents for more expensive reference products.
Read More
Survivors of Childhood Cancer More Likely to Be Undertreated for CVD Risk Factors
June 11th 2022Despite a greater risk of cardiovascular disease (CVD) due to exposure to chemotherapy and/or radiation, adult survivors of childhood cancer are undertreated for CVD risk factors compared with the general population.
Read More
FDA Approves Tisa-Cel for Third Indication, R/R Follicular Lymphoma
May 31st 2022Tisagenlecleucel (tisa-cel) was approved to treat adults with relapsed or refractory (R/R) follicular lymphoma. This is the third indication for the therapy since it became the first FDA-approved chimeric antigen receptor T-cell therapy in 2017.
Read More
Biologics Provide Opportunity to Manage Moderate to Severe Pediatric Asthma, Improve QOL
May 13th 2022Pediatric patients with asthma and their caregivers are faced with significant health and cost burdens, and biologics provide an opportunity to improve quality of life and asthma control, according to a panel of experts.
Read More
PET/CT Can Assess Early Treatment Response in Newly Diagnosed MM
May 12th 2022Negative positron emission tomography/CT examinations 6 months after induction therapy in patients with newly diagnosed multiple myeloma (MM) is associated with prolonged time to next treatment and overall survival.
Read More
Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's Oskouei
May 12th 2022Biosimilar adoption can be accelerated or stymied depending on actions taken by the managed care space, explained Sonia Oskouei, PharmD, vice president, biosimilars, Cardinal Health, during a session at Asembia’s Specialty Pharmacy Summit.
Read More